8-K: Tivic Health Partners with Fletcher Spaght to Accelerate Vagus Nerve Stimulation Commercialization

Tivic Health has partnered with Fletcher Spaght to develop a commercial strategy for its non-invasive cervical vagus nerve stimulation technology.

Summary

• Tivic Health has engaged Fletcher Spaght, a healthcare growth strategy firm, to accelerate the commercialization of its non-invasive cervical vagus nerve stimulation (ncVNS) technology.
• Fletcher Spaght will conduct a market assessment of Tivic Health's ncVNS technology, leveraging data from a Phase 1 trial.
• The assessment will explore approximately 30 potential medical applications across neurological, cardiac, psychiatric, and autonomic nervous system diseases.
• The partnership aims to refine Tivic Health's go-to-market strategy, clinical study plans, reimbursement pathways, and product development pipeline.
• The global vagus nerve stimulation market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, representing a 10.6% compound annual growth rate.
• The peripheral nerve stimulation segment, which Tivic Health targets, is expected to grow at a 35% CAGR, making it one of the fastest-growing areas in bioelectronic medicine.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic partnership, strong market growth projections, and promising technology. The engagement with a reputable firm like Fletcher Spaght adds credibility and suggests a well-planned approach to commercialization.

Positives

• The partnership with Fletcher Spaght is expected to provide valuable insights for Tivic Health's commercial strategy.
• The vagus nerve stimulation market is experiencing significant growth, presenting a substantial opportunity for Tivic Health.
• Tivic Health's ncVNS technology has demonstrated promising results in a Phase 1 trial.
• Fletcher Spaght's expertise in healthcare growth strategy is expected to accelerate Tivic Health's market entry.

Risks

• The success of the commercialization strategy depends on the accuracy of market assessments and clinical trial results.
• The company's ability to secure additional working capital may impact its ability to execute its plans.
• Changes in the relationship with Fletcher Spaght could affect the project's progress.
• The company faces risks related to clinical trial outcomes and regulatory approvals.

Future Outlook

Tivic Health expects to use the insights from the Fletcher Spaght engagement to drive its clinical strategy and product development in 2025 and beyond.

Management Comments

• FSI excels at projects like this, where our insights help clients like Tivic grow while improving patient healthcare, stated Bill Sigona, Partner at FSI.
• Bringing innovative technologies like ncVNS to market drives us, and we're excited to support Tivic's journey in advancing care across multiple therapeutic areas, added Bill Sigona.
• The work with Fletcher Spaght will help us sharpen our go-to-market strategy, clinical study plans, reimbursement pathway, and product development pipeline for our vagus nerve stimulation program, explained Jennifer Ernst, CEO of Tivic Health.
• The early outcomes from the engagement confirm there are significant market opportunities for our novel non-invasive bioelectronic therapies, said Jennifer Ernst.

Industry Context

This announcement highlights the growing interest and investment in bioelectronic medicine, particularly in non-invasive nerve stimulation therapies. The partnership with Fletcher Spaght indicates a strategic move by Tivic Health to capitalize on the expanding market for vagus nerve stimulation.

Comparison to Industry Standards

• The projected 10.6% CAGR for the global vagus nerve stimulation market is a strong indicator of growth, aligning with industry trends in bioelectronic medicine.
• The 35% CAGR forecast for peripheral nerve stimulation, where Tivic Health is focused, significantly exceeds the overall market growth rate, suggesting a high-potential niche.
• Companies like LivaNova and ElectroCore are established players in the broader neuromodulation market, but Tivic Health's focus on non-invasive cervical vagus nerve stimulation positions it uniquely.
• The engagement with Fletcher Spaght, a firm with a track record of launching companies and facilitating strategic transactions, suggests a serious commitment to commercial success, similar to other successful medical device startups.

Stakeholder Impact

• Shareholders may view the partnership positively, anticipating future revenue growth and market expansion.
• Employees may see this as a positive step towards the company's growth and success.
• Customers and patients may benefit from the development of new non-invasive treatment options.
• Suppliers and distributors may see increased business opportunities as the company expands its market presence.

Next Steps

• Fletcher Spaght will conduct a comprehensive market assessment of Tivic Health's ncVNS technology.
• Tivic Health will work with Fletcher Spaght to refine its go-to-market strategy, clinical study plans, and product development pipeline.
• Tivic Health expects to derive insights that will drive its clinical strategy and product development in 2025 and beyond.

Key Dates

Keywords

vagus nerve stimulation, bioelectronic medicine, peripheral nerve stimulation, commercial strategy, Fletcher Spaght, Tivic Health, ncVNS, market assessment, healthcare technology